Bicara Therapeutics Inc. 4

President and COO Ryan Cohlhepp exercised 18,750 options and sold a total of 28,750 Bicara Therapeutics Inc. (BCAX) common shares around $28.76–$30.35 under a Rule 10b5‑1 plan, ending with 181,641 shares owned.

On July 8, 2026, Bicara Therapeutics Inc. President and COO Ryan Cohlhepp exercised 18,750 stock options at $3.7898 per share and immediately sold the resulting common shares in multiple open‑market transactions, followed by a small additional sale on July 9, 2026, all pursuant to a Rule 10b5‑1 trading plan. The option exercise added 18,750 common shares at a low strike price, while same‑day sales of 22,833, 4,306, and 1,075 shares at weighted average prices of $28.7589, $29.7961, and $30.3549, respectively, plus a July 9 sale of 536 shares at $29.00, monetized a portion of his holdings but left him with 181,641 shares of common stock after the transactions. These trades appear to be a mix of routine option exercise and programmed profit‑taking, rather than an outright directional bet, and the footnotes indicate the sales were executed in multiple tranches within reported price ranges under a pre‑established plan.

Filing Facts

CIK

2023658

Ticker

BCAX

Form

4

Source Type

fda

Accession

0001470831-26-000701

Alert Tier

6